Service de Médecine Gériatrique of the Hôpital Edouard Herriot (Pavillon K)
Lyon, France
NCT Number: NCT05668663
Vitamin C is essential for numerous biological processes as it acts as a cofactor in various hydroxylation reactions, but also as a powerful antioxidant. As humans have lost the ability to synthetize Vitamin C, this micronutrient is found exclusively in the food, and more particularly in fresh fruits and vegetables.
The term 'hypovitaminosis C' refers to a plasmatic Vitamin C concentration < 28 µmol/L. It encompasses two distinct situations, according to the severity of the deprivation:
* A deeply lowered plasmatic concentration (< 11 µmol/L) is defined as 'Vitamin C deficiency'. The resulting condition is scurvy and its well-known haemorrhagic complications, very likely to be fatal. * A less low plasmatic concentration (11-27 µmol/L) is defined as 'Vitamin C depletion'. Symptoms are polymorphic and less suggestive, especially for elderly patients. Many studies suggest a chronic Vitamin C depletion may favour the occurrence of various conditions such as cognitive impairment, psychiatric disorders, cardio-vascular diseases, or certain cancers, thereby highlighting the involvement of Vitamin C in many biological processes.
The epidemiology and risk factors of hypovitaminosis C in ageing populations are poorly documented. The few studies dealing with this question are mostly retrospective, including a low number of patients, and relying on an imperfect methodology. Despite these limitations, data suggest hypovitaminosis C could concern up to 50% of the hospitalized geriatric population.
Despite this probably high prevalence, hypovitaminosis C is barely diagnosed and thus rarely supplemented. This is particularly true for the elderlies who are at risk high of being Vitamin C depleted.
Moreover, several risk factors have been described to be associated with Vitamin C depletion or deficiency, sometimes both. But only a few of them have been validated for the geriatric population.
Thus, there is a real need for a better understanding of hypovitaminosis C epidemiology and risk factors in the geriatric population, in order to diagnose earlier, more frequently, and more precisely these cases. It is important to note that an easy and safe supplementation exists (1 g of Vitamin C for 2 weeks).
A better understanding of risk factors is also a key element to apply corrective measures on modifiable risk factors in order to prevent the recurrence of hypovitaminosis C.
In the present research protocol, the investigators hypothesized hypovitaminosis C could concern half of the hospitalized geriatric patients in acute care units.
The primary objective of this study is to evaluate the prevalence of hypovitaminosis C in a geriatric acute care unit, by using a prospective design and including a statistically sufficient number of patients.
The secondary objectives are :
* To determine in this population the prevalence of Vitamin C deficiency, * To determine in this population the prevalence of Vitamin C depletion, * To assess the statistical associations between hypovitaminosis C, deficiency, and depletion with already known or pertinent risk factors. * To follow adverse events with vitamin C supplementation in deficient patients.
Looking for future studies?
Notify Me75 year and older
All sexes
Interventional
Not applicable
Lyon, France
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
If the patient consents to participate in the study, a 4-mL blood sample will be collected and performed when the patient enters the unit. No other sample will be taken, and the participation of the patient to the study will end after the result of the test or after the end of the vitamin C supplementation. A telephone call is organized to follow up on any adverse effects.
The blood sample will be collected up to 3 days after admission
Time frame: Day 1 : Ascorbemia will be measured only once for each patient, concomitantly with a general laboratory evaluation that will be performed when the patient enters the unit.
Ascorbemia will be classified as follows:
Time frame: Day 1 : Ascorbemia will be measured only once for each patient, concomitantly with a general laboratory evaluation that will be performed when the patient enters the unit.
For this secondary outcome, hypovitaminosis C will be divided into two sub-groups:
Time frame: No later than Day 0 : Data are systematically collected during the initial questioning. These data are not specific to the research project.
Information will be collected about the risk factors of interest for Hypovitaminosis C:
Time frame: No later than Day 0 : Data are systematically collected during the initial questioning. These data are not specific to the research project.
Time frame: No later than Day 0 : Data are systematically collected during the initial questioning. These data are not specific to the research project.
Time frame: A call will be made no later than 45 days after the sample is taken for patients supplemented with vitamin C.
The collection of adverse events from patients supplemented with Vitamin C either by a telephone call from the patient or from the department in which he/she is being treated.
Hospices Civils de Lyon
Other
Acronym: HYPO-VIT-C
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06983847
Acute Disease, Ascorbic Acid Deficiency
Vienna, Etc., Austria
View Trial DetailsNCT07285109
Ascorbic Acid Deficiency, Avitaminosis
Carlsbad, California, United States
View Trial DetailsNCT03807791
Ascorbic Acid Deficiency, Avitaminosis
Lyon, France
View Trial DetailsNCT04284696
Ascorbic Acid Deficiency, Avitaminosis
Vienna, Austria
View Trial Details